Oxaliplatin plus fluorouracil/leucovorin or sorafneib as first-line treatments for advanced hepatocellular carcinoma: a cost-effectiveness analysis.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.e18270 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. e18270-e18270

Author(s):

Pengfei Zhang ◽

Feng Wen ◽

Qiu Li

Keyword(s):

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Advanced Hepatocellular Carcinoma ◽

Effectiveness Analysis

Download Full-text

FOLFOX4 or sorafenib as the first-line treatments for advanced hepatocellular carcinoma: A cost-effectiveness analysis

Digestive and Liver Disease ◽

10.1016/j.dld.2016.07.007 ◽

2016 ◽

Vol 48 (12) ◽

pp. 1492-1497 ◽

Author(s):

Pengfei Zhang ◽

Feng Wen ◽

Qiu Li

Keyword(s):

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Advanced Hepatocellular Carcinoma ◽

Effectiveness Analysis

Download Full-text

P-2 First-line atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma: A cost-effectiveness analysis

Annals of Oncology ◽

10.1016/j.annonc.2021.05.057 ◽

2021 ◽

Vol 32 ◽

pp. S97

Author(s):

S. Chan ◽

C. Chiang ◽

S. Lee ◽

H. Choi

Keyword(s):

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis

Download Full-text

Atezolizumab and bevacizumab combination compared with sorafenib as the first‐line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost‐effectiveness analysis in China and the United states

Liver International ◽

10.1111/liv.14795 ◽

2021 ◽

Vol 41 (5) ◽

pp. 1097-1104

Author(s):

Feng Wen ◽

Hanrui Zheng ◽

Pengfei Zhang ◽

Weiting Liao ◽

Kexun Zhou ◽

...

Keyword(s):

United States ◽

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Systemic Treatment ◽

The United States ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Unresectable Hepatocellular Carcinoma

Download Full-text

PCN77 COST EFFECTIVENESS ANALYSIS OF LENVATINIB FOR THE FIRST-LINE TREATMENT OF INDIVIDUALS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA

Value in Health ◽

10.1016/j.jval.2020.04.1579 ◽

2020 ◽

Vol 23 ◽

pp. S37

Author(s):

X. Li ◽

G. Wudong ◽

Y. Wang

Keyword(s):

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Line Treatment ◽

Effectiveness Analysis ◽

Unresectable Hepatocellular Carcinoma ◽

First Line Treatment

Download Full-text

Cost-Effectiveness Analysis of Oxaliplatin Plus Fluorouracil/Leucovorin (Folfox4) Compared to Sorafenib for Treatment of Advanced Hepatocellular Carcinoma Patients in China

Value in Health ◽

10.1016/j.jval.2016.08.277 ◽

2016 ◽

Vol 19 (7) ◽

pp. A889

Author(s):

SK Qin ◽

E Kruger ◽

SC Tan ◽

SQ Cheng ◽

XX Yao ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Advanced Hepatocellular Carcinoma ◽

Effectiveness Analysis

Download Full-text

Cost-Effectiveness Analysis of Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres versus Sorafenib in Advanced Hepatocellular Carcinoma

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2018.07.1185 ◽

2018 ◽

Vol 102 (3) ◽

pp. e402 ◽

Author(s):

K.E. Marqueen ◽

C. Ang ◽

M. Mazumdar ◽

M. Buckstein ◽

B.S. Ferket

Keyword(s):

Hepatocellular Carcinoma ◽

Radiation Therapy ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Advanced Hepatocellular Carcinoma ◽

Selective Internal Radiation Therapy ◽

Internal Radiation ◽

Effectiveness Analysis ◽

Resin Microspheres ◽

Download Full-text

Cost‐effectiveness analysis of cabozantinib as second‐line therapy in advanced hepatocellular carcinoma

Liver International ◽

10.1111/liv.14257 ◽

2019 ◽

Vol 39 (12) ◽

pp. 2408-2416 ◽

Author(s):

Weiting Liao ◽

Jiaxing Huang ◽

David Hutton ◽

Guiqi Zhu ◽

Qiuji Wu ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Advanced Hepatocellular Carcinoma ◽

Second Line ◽

Second Line Therapy ◽

Effectiveness Analysis ◽

Download Full-text

Sorafenib for advanced hepatocellular carcinoma (HCC) in the public health setting in Brazil: a cost-effectiveness analysis

Annals of Oncology ◽

10.1093/annonc/mdz155.238 ◽

2019 ◽

Vol 30 ◽

pp. iv66

Author(s):

A. Sasse ◽

R. Carmo

Keyword(s):

Public Health ◽

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Advanced Hepatocellular Carcinoma ◽

Effectiveness Analysis ◽

Public Health Setting

Download Full-text

Cost Effectiveness Analysis of Sorafenib Versus Best Supportive Care in Patients with Advanced Hepatocellular Carcinoma from Health Care System Perspective in Egypt

Value in Health ◽

10.1016/j.jval.2017.08.235 ◽

2017 ◽

Vol 20 (9) ◽

pp. A439

Author(s):

Elkony ◽

GH Elsisi

Keyword(s):

Hepatocellular Carcinoma ◽

Health Care ◽

Cost Effectiveness ◽

Supportive Care ◽

Health Care System ◽

Best Supportive Care ◽

Cost Effectiveness Analysis ◽

Advanced Hepatocellular Carcinoma ◽

System Perspective ◽

Effectiveness Analysis

Download Full-text

Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China

Cost Effectiveness and Resource Allocation ◽

10.1186/s12962-018-0112-0 ◽

2018 ◽

Vol 16 (1) ◽

Author(s):

Shukui Qin ◽

Eliza Kruger ◽

Seng Chuen Tan ◽

Shuqun Cheng ◽

Nanya Wang ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Advanced Hepatocellular Carcinoma ◽

Effectiveness Analysis

Download Full-text